Read More 6 minute read Pharma Industry News Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation. bySoujanya RaviOctober 23, 2025